PT  - JOURNAL ARTICLE
AU  - Zhao, Shilei
AU  - Sha, Tong
AU  - Xue, Yongbiao
AU  - Chen, Hua
TI  - Flattening the Curve is Imperative: When China Relaxes the Dynamic Zero COVID-19 Policy
AID  - 10.1101/2022.12.15.22283335
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.15.22283335
4099  - http://medrxiv.org/content/early/2022/12/17/2022.12.15.22283335.short
4100  - http://medrxiv.org/content/early/2022/12/17/2022.12.15.22283335.full
AB  - Since December 7, 2022, China relaxed the strict dynamic zero COVID-19 policy. Here we quantitatively analyze its potential impacts on COVID-19 trend with the epidemiological model SUVQC using the population and parameter settings of Beijing as a case. Our results indicate that if non-pharmacological interventions are completely ceased, the ICU bed demand number will peak in 26 days at ∼23.88 thousand, which is 18 times the total number of ICU beds in Beijing. COVID-19 Omicron will cause 31,817 deaths in Beijing in the first year. We urge that the flattening curve strategy is necessary to slow down the infection and avoid overwhelming the healthcare system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://voice.baidu.com/act/newpneumonia/newpneumonia/ https://ourworldindata.org/covid-vaccinations